Beth Hecht, See Remarks at Xeris Biopharma Holdings, Inc. (XERS), sold 33,334 shares at $7.01 ($234K) on 2025-12-01, disclosed to the SEC on 2025-12-02.
Scheduled sale ($234k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.01 | 16,667 | $117K | 50.0% |
| 2 | $7.01 | 16,667 | $117K | 50.0% |
| Total | $7.01 avg | 33,334 | $234K | 100% |
| Filing → |
| XERS | SELL | 2026-07-02 | $134K | — | Filing → |
| XERS | SELL | 2026-06-02 | $101K | — | Filing → |
| XERS | SELL | 2026-05-01 | $104K | — | Filing → |